FALSE000171127900017112792024-05-212024-05-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2024
KRYSTAL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-38210 82-1080209
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification Number)
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (412) 586-5830

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockKRYSNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 17, 2024, Krystal Biotech, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter.

Proposal One: Election of Class I Directors

The Company’s stockholders elected Suma M. Krishnan, Julian S. Gangolli, and Catherine Mazzacco as members of the Company’s Board of Directors as Class I directors for a three-year term. The results of the vote were as follows:
NomineeVotes ForVotes WithheldBroker Non-Votes
Suma M. Krishnan21,058,0041,498,0172,244,047
Julian S. Gangolli17,226,0675,329,9542,244,047
Catherine Mazzacco20,382,9242,173,0972,244,047

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the vote were as follows:
Votes ForVotes AgainstAbstentions
24,769,8387,43822,792

Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation

The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2023, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
21,697,311851,6907,0202,244,047



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: May 21, 2024  KRYSTAL BIOTECH, INC.
  By: /s/ Krish S. Krishnan
  Name: Krish S. Krishnan
  Title: Chairman and Chief Executive Officer


v3.24.1.1.u2
Cover
May 21, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 21, 2024
Entity Registrant Name KRYSTAL BIOTECH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38210
Entity Tax Identification Number 82-1080209
Entity Address, Address Line One 2100 Wharton Street
Entity Address, Address Line Two Suite 701
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15203
City Area Code 412
Local Phone Number 586-5830
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001711279
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock
Trading Symbol KRYS
Security Exchange Name NASDAQ
Document Information [Line Items]  
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false

Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Krystal Biotech Charts.
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Krystal Biotech Charts.